Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.
To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:
Target Disease Indication
- Breast Cancer
- Chronic Lymphocytic Leukemia
- Colorectal Cancer
- Head and Neck Cancer
- Lung Cancer
- Lupus Nephritis
- Melanoma
- Multiple Myeloma
- Primary Sjögren's Syndrome
- Others
Target Immune Checkpoint
- B7-H3
- CD38
- CD40
- CD47
- Others
Mechanism of Action
- Inhibitory
- Stimulatory
Therapeutic Modality
- Monoclonal Antibody
- Small Molecule
Type of Therapy
- Monotherapy
- Combination Therapy
Route of Administration
- Intravenous
- Subcutaneous
- Others
Key Geographical Regions
- North America
- Europe
- Asia-Pacific and the Rest of the World
The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030. report features the following companies, which we identified to be key players in this domain:
Bristol Myers Squibb
GlaxoSmithKline
Incyte
Novartis
Trillium Therapeutics
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Current Market Landscape: Clinical and Preclinical Molecules
5. Market Landscape: Therapies Targeting Cd47
6. Market Landscape: Therapies Targeting 4-1bb
7. Clinical Trial Analysis
8. Company Profiles: Next Generation Inhibitors and Stimulators
9. Academic Grants Analysis
10. Partnerships and Collaborations
11. Target Competitiveness Analysis
12. Big Pharma Initiatives
13. Market Forecast and Opportunity Analysis
14. Concluding Remarks
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
